Baseline Characteristics for Study Cohort and Subcohorts of Responders and Nonresponders
| Parameter | All patients (n = 14) | Responders (n = 7) | Nonresponders (n = 7) | P |
| Age (y) | 67.9 ± 8.4 | 68.0 ± 8.8 | 67.7 ± 8.7 | NS |
| Men | 12 (86) | 6 (86) | 6 (86) | NS |
| Angiotensin-converting enzyme inhibitor | 13 (93) | 7 (100) | 6 (86) | NS |
| β-blocker | 13 (93) | 6 (86) | 7 (100) | NS |
| Diuretics | 10 (71) | 4 (57) | 6 (86) | NS |
| Aldosterone receptor antagonist | 8 (57) | 4 (50) | 4 (50) | NS |
| Clinical evaluation | ||||
| NYHA class before CRT | 3.0 ± 0.0 | 3.0 ± 0.0 | 3.0 ± 0.0 | NS |
| NYHA class after CRT | 2.6 ± 0.6 | 2.0 ± 0.0 | 3.1 ± 0.4 | <0.05 |
| Δ NYHA class* | −0.4 ± 0.6 | −1.0 ± 0.3 | +0.1 ± 0.4 | <0.05 |
| Brain natriuretic peptide before CRT (pg/mL) | 625 ± 514 | 691 ± 582 | 560 ± 473 | NS |
| Brain natriuretic peptide after CRT (pg/mL) | 432 ± 533 | 236 ± 257 | 628 ± 679 | NS |
| Δ Brain natriuretic peptide (pg/mL) | −193 ± 467 | −454 ± 416 | +68 ± 373 | <0.05 |
| Echocardiographic parameters | ||||
| LVEF before CRT (%) | 25 ± 8 | 24 ± 9 | 27 ± 8 | NS |
| LVEF after CRT (%) | 32 ± 13 | 39 ± 14 | 26 ± 8 | NS |
| Δ LVEF (%) | +7 ± 12 | +15 ± 11 | −1 ± 7 | <0.05 |
| LVESV before CRT (mL) | 219 ± 57 | 231 ± 64 | 206 ± 52 | NS |
| LVESV after therapy (mL) | 177 ± 65 | 150 ± 51 | 205 ± 70 | 0.073 |
| Δ LVESV (mL)* | −41 ± 51 | −82 ± 37 | +1 ± 24 | <0.05 |
| Residual dyssynchrony | 7 (50) | 2 (29) | 5 (71) | |
| PET/CT including phase analysis | ||||
| Scar burden (%) | 20 ± 19 | 10 ± 8 | 30 ± 21 | <0.05 |
| Lead over scar | 4 (29) | 0 (0) | 4 (57) | |
| Bandwidth (°) | 90 ± 38 | 91 ± 28 | 89 ± 48 | NS |
| Phase SD (°) | 38 ± 11 | 42 ± 8 | 34 ± 14 | NS |
| Phase entropy (°) | 80 ± 5 | 77 ± 4 | 83 ± 3 | <0.05 |
↵* Prespecified response criteria.
NS = not significant.
Values are expressed as n, with percentages in parentheses, or mean ± SD.